Ariad Pharmaceuticals, Inc. (ARIA) Among The Biotech Players To Watch

Page 1 of 2

Three biotech companies are making themselves heard in the stock market. They are making a mark in the life sciences space with their unique mix of science and strategy.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is on the focused approach trajectory, using its solid foundation in the sciences to fill the holes left open by big pharma. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is exercising first-mover advantage by developing a novel but potent approach to disease treatment. Array BioPharma Inc (NASDAQ:ARRY) is utilizing the overlaps in research areas to hasten the speed and increase the likelihood of drug discovery while attacking diseases in a more effective manner.

What are these companies doing differently?

On the face of it, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) doesn’t seem to be following the path of diversification. It has selected a specific market (a very large one at that) – cancer. However, cancer can be of several types, and it has been increasingly plaguing the world for the past few years.

Within the realm of cancer, Ariad has lot of opportunities to diversify. In fact, staying under the cancer umbrella will allow it to benefit from the overlap in research areas among various types of cancers, which could help in developing therapies sooner and for multiple variations of the disease.

The second good thing Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is doing (commercially) is targeting the needs not met by existing big pharma medications. The idea is to find out the strengths of the best-selling big pharma medications and beat them to take over the market.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)Following a different path, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has figured out a novel and potent way to attack disease. The body already has a system in place to fight diseases – our immune system. So, why not create a platform of potent antibodies and immunomodulators (immune response modulators) that can be used to develop novel drugs and drug combinations for disease treatment?

They would be the first-in-the-market to utilize such an approach to treat complicated diseases. While Celldex Therapeutics, Inc. (NASDAQ:CLDX) is acquiring smaller companies like CuraGen to add to its collection of antibodies, it is also partnering with companies like Pfizer Inc. (NYSE:PFE) to obtain the financial resources and expertise to develop potential therapy candidates.

Array Biopharma Inc (NASDAQ:ARRY), charting its own course, has channeled its efforts towards cancer and inflammatory disease. These two research areas have a lot of potential for overlap, which can lead to faster development of medications. The company seeks to develop first-in-class drugs, targeting important players in already identified molecular pathways. They also look at increasing the efficacy and safety of existing drugs, or improving upon drugs currently in clinical development by creating superior clinical candidates.

News and financials

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Ariad recently presented new preclinical data which shows that its recently approved drug, Iclusig (ponatinib), overcomes drug-resistant mutations found in gastrointestinal stromal tumors. The company currently has four drugs in its pipeline developed in-house, which are being explored for various indications.

The company reported a net loss of $220.9 million for FY 2012, while loss in FY 2011 was $123.6 million. Its operating expenses increased by $103.5 million in 2012 from 2011. This increase was attributed to the development of the company’s product candidates and the preparations involved in the commercial launch of their drug Iclusig.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

On April 8, Celldex presented positive data showing that their drug candidate, CDX-1127, is effective in activating a patient’s own T cells (type of cell that plays an important role in immune response) against their cancer.

The company incurred a $14.3 million loss in 2012 compared to 2011, mainly due to increased R&D expenditure, especially for late-stage trials. General and administration expenses increased by $0.8 million in 2012 compared to 2011, primarily due to increased personnel-related expenses and rindopepimut-commercialization planning.

Array Biopharma Inc (NASDAQ:ARRY)

Array Biopharma recently reported positive results on two ongoing trials on drug candidates for multiple myeloma. Results of both trials showed that the drug was well tolerated in patients as single agent and in combination therapy. The drug in question, ARRY-520, is a strong multiple myeloma drug with a distinct mechanism of action compared to existing medications.

Revenue has been going up consistently for the past four years, however, the company still operates at a loss. The company has been able to rein in its operating expenses by about 24%.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!